Your browser doesn't support javascript.
loading
Simultaneous Targeting of DNA Polymerase Theta and PARP1 or RAD52 Triggers Dual Synthetic Lethality in Homologous Recombination-Deficient Leukemia Cells.
Sullivan-Reed, Katherine; Toma, Monika M; Drzewiecka, Malgorzata; Nieborowska-Skorska, Margaret; Nejati, Reza; Karami, Adam; Wasik, Mariusz A; Sliwinski, Tomasz; Skorski, Tomasz.
Afiliação
  • Sullivan-Reed K; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania.
  • Toma MM; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania.
  • Drzewiecka M; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania.
  • Nieborowska-Skorska M; Laboratory of Medical Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
  • Nejati R; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania.
  • Karami A; Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Wasik MA; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania.
  • Sliwinski T; Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Skorski T; Laboratory of Medical Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Mol Cancer Res ; 21(10): 1017-1022, 2023 10 02.
Article em En | MEDLINE | ID: mdl-37358557
ABSTRACT
DNA polymerase theta (Polθ, encoded by POLQ gene) plays an essential role in Polθ-mediated end-joining (TMEJ) of DNA double-strand breaks (DSB). Inhibition of Polθ is synthetic lethal in homologous recombination (HR)-deficient tumor cells. However, DSBs can be also repaired by PARP1 and RAD52-mediated mechanisms. Because leukemia cells accumulate spontaneous DSBs, we tested if simultaneous targeting of Polθ and PARP1 or RAD52 enhance the synthetic lethal effect in HR-deficient leukemia cells. Transformation potential of the oncogenes inducing BRCA1/2-deficiency (BCR-ABL1 and AML1-ETO) was severely limited in Polq-/-;Parp1-/- and Polq-/-;Rad52-/- cells when compared with single knockouts, which was associated with accumulation of DSBs. Small-molecule inhibitor of Polθ (Polθi) when combined with PARP or RAD52 inhibitors (PARPi, RAD52i) caused accumulation of DSBs and exerted increased effect against HR-deficient leukemia and myeloproliferative neoplasm cells. IMPLICATIONS In conclusion, we show that PARPi or RAD52i might improve therapeutic effect of Polθi against HR-deficient leukemias.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia / Mutações Sintéticas Letais Limite: Humans Idioma: En Revista: Mol Cancer Res Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia / Mutações Sintéticas Letais Limite: Humans Idioma: En Revista: Mol Cancer Res Ano de publicação: 2023 Tipo de documento: Article